A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose

(2013) M. D. Snape et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Controlling serogroup B invasive meningococcal disease: the Canadian perspective

(2013) Julie A Bettinger et al.   Expert Review of Vaccines

The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative

(2013) Marco Aurélio P Sáfadi et al.   Expert Review of Vaccines

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

(2013) Timo Vesikari et al.   LANCET

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

(2013) Ulrich Vogel et al.   LANCET INFECTIOUS DISEASES

Neisseria meningitidis serogroup B vaccine development

(2013) Nicole M. Caesar et al.   MICROBIAL PATHOGENESIS

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

(2013) Giacomo Frosi et al.   VACCINE

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

(2013) Helen S. Marshall et al.   VACCINE

Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine

(2013) Maria Elena Santolaya et al.   Human Vaccines & Immunotherapeutics

Letter from the Editor

(2013) Ronald W. Ellis et al.   Human Vaccines & Immunotherapeutics

Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines

(2012) Brian D. Plikaytis et al.   Clinical and Vaccine Immunology

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

(2012) Nicoletta Gossger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

(2012) María Elena Santolaya et al.   LANCET

Meningococcal serogroup B vaccines: will they live up to expectations?

(2011) Wendell D Zollinger et al.   Expert Review of Vaccines

Extensive Genomic Variation within Clonal Complexes of Neisseria meningitidis

(2011) Weilong Hao et al.   Genome Biology and Evolution

The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans

(2011) Daniela Toneatto et al.   Human vaccines & immunotherapeutics

The changing and dynamic epidemiology of meningococcal disease

(2011) Scott A. Halperin et al.   VACCINE

The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology

(2010) Vanessa N Racloz et al.   BMC INFECTIOUS DISEASES

Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates

(2010) Alan Kimura et al.   Clinical and Vaccine Immunology

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

(2010) Jamie Findlow et al.   CLINICAL INFECTIOUS DISEASES

Review of Meningococcal Group B Vaccines

(2010) Dan M. Granoff   CLINICAL INFECTIOUS DISEASES

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

(2010) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

(2010) J. Donnelly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

(2009) Johan Holst et al.   VACCINE

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE